Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1975-10-21
pubmed:abstractText
Twenty-two patients with Parkinsonism were treated with levoamphetamine and 12 of these with dextroamphetamine. Levoamphetamine resulted in a significant improvement in disability from Parkinsonism, although the reduction in total disability, tremor, akinesia, and rigidity scores was slight (ca 20 percent). Dextroamphetamine in lower dosage also reduced disability by some 17 percent. The most disabled patients, including those also on levodopa, showed the greatest response to amphetamines. Previously, amphetamines have been reported to be a selective treatment for the oculogyric crises of post-encephalitic Parkinsonism. Amphetamines are thought to cause the release of catecholamines from central neurones. Their action in Parkinson's disease may be limited because of pre-existing striatal dopamine deficiency. Side-effects of amphetamines, anorexia, and CNS stimulation are different from those caused by levodopa in patients with Parkinson's disease.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/1097600-13710856, http://linkedlifedata.com/resource/pubmed/commentcorrection/1097600-14195468, http://linkedlifedata.com/resource/pubmed/commentcorrection/1097600-14213112, http://linkedlifedata.com/resource/pubmed/commentcorrection/1097600-14334290, http://linkedlifedata.com/resource/pubmed/commentcorrection/1097600-17768920, http://linkedlifedata.com/resource/pubmed/commentcorrection/1097600-4405376, http://linkedlifedata.com/resource/pubmed/commentcorrection/1097600-4533510, http://linkedlifedata.com/resource/pubmed/commentcorrection/1097600-4625014, http://linkedlifedata.com/resource/pubmed/commentcorrection/1097600-4686111, http://linkedlifedata.com/resource/pubmed/commentcorrection/1097600-4691682, http://linkedlifedata.com/resource/pubmed/commentcorrection/1097600-4730376, http://linkedlifedata.com/resource/pubmed/commentcorrection/1097600-5694457
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Mar
pubmed:issn
0022-3050
pubmed:author
pubmed:issnType
Print
pubmed:volume
38
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
232-7
pubmed:dateRevised
2010-9-3
pubmed:meshHeading
pubmed:year
1975
pubmed:articleTitle
Amphetamines in the treatment of Parkinson's disease.
pubmed:publicationType
Journal Article, Clinical Trial, Controlled Clinical Trial